Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Avinger gets up to $40mm in mezzanine financing

Executive Summary

PDL BioPharma Inc. (cancer and immune therapeutics) has agreed to provide cardiovascular device developer Avinger Inc. with up to $40mm in a mezzanine financing. Avinger gets $20mm at closing and the remainder when it achieves certain revenue milestones. In exchange, PDL gets interest on the principal amount outstanding and a low single-digit royalty based on Avinger’s revenues through April 2018. The money will be used to continue developing and eventually commercialize Avinger’s Ocelot and Lightbox lumivascular technologies, and to develop Pantheris, its next-generation lumivascular atherectomy device. Avinger’s technologies provide intravascular imaging within an interventional cardiovascular device. A physician is then able to view real-time images of the inside of an artery. Last July Avinger brought in $33mm through its Series D round.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Venture Financing

Related Companies